Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roivant Sciences GMBH

www.roivant.com

Latest From Roivant Sciences GMBH

Deals Shaping the Medical Industry, January 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2017.

Deals BioPharmaceutical

Axovant's Cupboard Is Bare After Lead Dementia Program Fails

'New year, new me' is a mantra to be adopted by Swiss drug developer Axovant as it seeks new products to fill its pipeline. The CNS-focused company is floundering having ended development of its lead compound intepirdine following another clinical trial failure.

Clinical Trials Neurology

The Year's Clinical Trials In Review: Big Misses In 2017

The big clinical trial setbacks hurt. Scrip takes a look back at the painful clinical trial failures this year, with Axovant's intepirdine and Celgene's mongersen topping the list.

ImmunoOncology Clinical Trials

Deal Watch: Boehringer's Busy End Of Year Includes Deals With Roche, Autifony

The German pharma options potassium channel modulator technology from Autifony and partners with Roche on immunological approaches to irritable bowel syndrome. Roche unveils discovery pacts with Confo and DiCE.

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Hepatic (Liver)
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Roivant Sciences Inc.
  • Roivant Sciences Ltd.
  • Valor Biotechnology
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Roivant Sciences GMBH
  • Senior Management
  • Vivek Ramaswamy, CEO
    Lawrence T Friedhoff, MD, PhD, Chief, R&D
    Matthew Gline, SVP, Fin. & Bus. Operations
    Mayukh Sukhatme, MD, CBO
  • Contact Info
  • Roivant Sciences GMBH
    Phone: 61 225 44 82
    Viaduktstrasse 8
    Basel, 4051
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register